Amyloidosis Research Consortium
A 501(c)(3) nonprofit founded in 2015 in Newton, Massachusetts, ARC works to speed development of and access to treatments for systemic amyloidosis through collaboration with patients, clinicians, industry and regulators.
The Amyloidosis Research Consortium (ARC) is a 501(c)(3) nonprofit founded in 2015 and headquartered in Newton, Massachusetts. It works to accelerate the development of and access to new and innovative treatments for systemic amyloidosis, a rare disease, by bringing together patients, clinicians, industry and regulators. Its activities span rare disease research, clinical trial development, drug development acceleration, regulatory engagement and patient care resources.
Among ARC's outputs is My Amyloidosis Pathfinder, a tool designed to help patients locate personalised treatment centres and clinical trials. The organisation reports a decade of collaboration building across industry, research, clinical care and regulatory sectors.
ARC describes its culture as mission-driven, with an emphasis on collaboration and innovation and on patient empowerment and support. Its stated commitment is to improving the lives of people affected by amyloidosis.